HGF/c-Met raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-18 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
=== Pharmacodynamics === Myristicin interferes with multiple signaling pathways and enzyme processes in the body. It is known to be a weak inhibitor of monoamine oxidase (MAO), an enzyme in humans that metabolizes neurotransmitters (for example, serotonin, dopamine, epinephrine, and norepinephrine). It lacks the basic nitrogen atom that is typical of monoamine oxidase inhibitors (MAOIs), potentially explaining a weaker inhibitory effect. While smaller concentrations of MAOIs may not cause problems, there are additional warnings regarding drug interactions. Those taking antidepressants that are MAOIs (such as phenelzine, isocarboxazid, tranylcypromine or selegiline) or taking selective serotonin reuptake inhibiting (SSRI) antidepressants should avoid essential oils rich in myristicin, such as that of nutmeg and anise. Myristicin does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. In laboratory studies, myristicin is cytotoxic. Specifically, it stimulates cytochrome c release, which activates caspase cascades and induces early apoptosis in the cells. Myristicin has also been shown to inhibit cytochrome P450 enzymes, which are responsible for metabolizing a variety of substrates including hormones and toxins, allowing these substrates to accumulate. The pharmacology of myristicin and other nutmeg constituents has been reviewed.
Some plants such as willow trees and poplars have been found to clean both lead and cadmium from soil. Typical background concentrations of cadmium do not exceed 5 ng/m3 in the atmosphere; 2 mg/kg in soil; 1 μg/L in freshwater and 50 ng/L in seawater. Concentrations of cadmium above 10 μg/L may be stable in water having low total solute concentrations and pH and can be difficult to remove by conventional water treatment processes.
"Cellulose" . Encyclopædia Britannica. Vol. 5 (11th ed.). 1911. Structure and morphology of cellulose by Serge Pérez and William Mackie, CERMAV-CNRS Cellulose, by Martin Chaplin, London South Bank University Clear description of a cellulose assay method at the Cotton Fiber Biosciences unit of the USDA. Cellulose films could provide flapping wings and cheap artificial muscles for robots – TechnologyReview.com
The endoplasmic reticulum (ER) is a part of a transportation system of the eukaryotic cell, and has many other important functions such as protein folding. The word endoplasmic means "within the cytoplasm", and reticulum is Latin for "little net". It is a type of organelle made up of two subunits – rough endoplasmic reticulum (RER), and smooth endoplasmic reticulum (SER). The endoplasmic reticulum is found in most eukaryotic cells and forms an interconnected network of flattened, membrane-enclosed sacs known as cisternae in the RER, and tubular structures in the SER. The membranes of the ER are continuous with the outer nuclear membrane. The endoplasmic reticulum is not found in red blood cells, or spermatozoa. There are two types of ER that share many of the same proteins and engage in certain common activities such as the synthesis of certain lipids and cholesterol. Different types of cells contain different ratios of the two types of ER depending on the activities of the cell. RER is found mainly toward the nucleus of the cell and SER towards the cell membrane or plasma membrane of the cell. The outer (cytosolic) face of the RER is studded with ribosomes that are the sites of protein synthesis. The RER is especially prominent in cells such as hepatocytes. The SER lacks ribosomes and functions in lipid synthesis but not metabolism, the production of steroid hormones, and detoxification. The SER is especially abundant in mammalian liver and gonad cells. The ER was observed by light microscopy by Charles Garnier in 1897, who coined the term ergastoplasm.
Sources: en.wikipedia.org
The pore sizes of technical membranes are specified differently depending on the manufacturer. One common distinction is by nominal pore size. It describes the maximum pore size distribution and gives only vague information about the retention capacity of a membrane. The exclusion limit or "cut-off" of the membrane is usually specified in the form of NMWC (nominal molecular weight cut-off, or MWCO, molecular weight cut off, with units in Dalton). It is defined as the minimum molecular weight of a globular molecule that is retained to 90% by the membrane. The cut-off, depending on the method, can by converted to so-called D90, which is then expressed in a metric unit. In practice the MWCO of the membrane should be at least 20% lower than the molecular weight of the molecule that is to be separated. Using track etched mica membranes Beck and Schultz demonstrated that hindered diffusion of molecules in pores can be described by the Rankin equation. Filter membranes are divided into four classes according to pore size:
He continued updating this publication to 2010, and it with its research documents and notes, including about half a million press cuttings, is now archived at the Bishopsgate Institute. William Rothenstein (29 January 1872 – 14 February 1945), painter, printmaker, draughtsman, lecturer, writer on art; wrote several critical books and pamphlets, including Goya; the first English monograph on the artist), A Plea for a Wider Use of Artists & Craftsmen and Whither Painting; published three volumes of memoirs: Men and Memories, Vol I and II and Since Fifty. Men and Memories Volume I includes anecdotes about Oscar Wilde and many other friends of Rothenstein's, including Max Beerbohm, James Whistler, Paul Verlaine, Edgar Degas, and John Singer Sargent. Hannah Rothschild (born 22 May 1962), daughter of Jacob Rothschild, 4th Baron Rothschild, author, businesswoman, philanthropist and documentary filmmaker, has written screenplays and journalism, a biography and two novels; serves on charitable and financial boards and is first female to chair the Board of Trustees of the National Gallery in London;liaison trustee for the Tate Gallery;trustee of the Whitechapel Gallery;chair of Yad Hanadiv in Israel; directed films for Saturday Review, Arena and Omnibus; has written for The Times, The New York Times, The Observer, The Guardian, Daily Telegraph, Vanity Fair, Vogue, The Spectator and Harper's Bazaar, Financial Times, Elle, Washington Post and others.
== Activities == The CSCC monitors the quality of testing services and acts as technical experts to evaluate and select methods and instrumentation. They apply their clinical and technical knowledge to assist physicians in selecting and interpreting tests, as well as supporting the laboratory's research and teaching activities. The society also produces publications, including the scientific journal Clinical Biochemistry, a member newsletter CSCC News, and position papers on current issues such as cardiac troponin testing. Special interest groups have been developed to advance knowledge and produce solutions in Clinical Toxicology, Point-Of-Care Testing, Pediatric and Perinatal Biochemistry, Monoclonal Gammopathy, Autoverification of test results, and the Canadian Laboratory Initiative on Paediatric Reference Intervals - CALIPER.
Sources: en.wikipedia.org
=== Legal status === On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for melphalan. The applicant for this medicinal product is Adienne S.r.l. S.U. Melphalan was approved for medical use in the European Union in November 2020.
==== In venoms ==== Serotonin is a common component of invertebrate venoms, salivary glands, nervous tissues, and various other tissues, across molluscs, insects, crustaceans, scorpions, various kinds of worms, and jellyfish. Adult Rhodnius prolixus – hematophagous on vertebrates – secrete lipocalins into the wound during feeding. In 2003 these lipocalins were demonstrated to sequester serotonin to prevent vasoconstriction (and possibly coagulation) in the host.
=== 1980s === Biomedical research in the 1980s was characterized by rapid advances in molecular diagnostics and genetic engineering. In 1983, Kary Mullis invented the Polymerase Chain Reaction (PCR), a technique that enabled the exponential amplification of specific DNA sequences. PCR revolutionized medical diagnostics, forensic science, and molecular genetics. The decade was also defined by the biomedical response to the HIV/AIDS epidemic following the identification of the human immunodeficiency virus in 1983 and 1984 by Luc Montagnier, Françoise Barré-Sinoussi and Robert Gallo. Additionally, recombinant human insulin, approved in 1982, became the first commercially available medication produced through recombinant DNA technology.
== Chemistry == MCCAM, also known as O-methylclocinnamox, is structurally related to the MOR irreversible antagonists clocinnamox (CCAM) and methocinnamox (MCAM). CCAM and its analogues were derived by structural modification of buprenorphine.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.